Latest news with #Avant
Cision Canada
2 days ago
- Business
- Cision Canada
Healthcare's Quiet AI Boom Is Creating a New Class of Breakout Contenders
VANCOUVER, BC, May 27, 2025 /CNW/ -- Equity Insider News Commentary – Artificial intelligence is rapidly becoming one of the most promising frontiers in healthcare innovation. Ark Invest's Cathie Wood recently pointed to breakthrough research from Mass General Brigham —where AI models identified cancer survival outcomes using facial photographs—as evidence that healthcare may become AI's " most profound application." As adoption moves from theory to practice, several tech and biotech players are already making real-world strides. Recent developments have come from Avant Technologies, Inc. (OTCQB: AVAI), Butterfly Network, Inc. (NYSE: BFLY), AptarGroup, Inc. (NYSE: ATR), AstraZeneca PLC (NASDAQ: AZN), and Relay Therapeutics, Inc. (NASDAQ: RLAY). According to Statista, the global economic impact of AI in healthcare stood at roughly $11 billion—but that figure is projected to reach $188 billion by 2030, representing a staggering 37% CAGR. Accenture forecasts an even greater long-term influence, estimating that AI could add $461 billion in value to the global healthcare sector by 2035. This surge in AI integration is unfolding within a system already projected to exceed $2.26 trillion—placing advanced diagnostics, early detection, and intelligent therapeutics at the heart of the next evolution in patient care. Avant Technologies, Inc. (OTCQB: AVAI), in partnership with Ainnova Tech, is working to position itself as a next-generation leader in predictive healthcare. Through its flagship platform, Vision AI, the company is developing a suite of AI-powered diagnostic tools aimed at detecting disease early—often before symptoms appear. Most recently, Avant announced it is exploring the integration of a patented technology designed for the early detection of dementia, marking a major expansion of its preventative screening capabilities. The proposed technology combines machine learning algorithms with hardware and a five-minute blood test to identify dementia-related risk factors well before traditional diagnoses. Avant is currently evaluating whether to acquire the intellectual property outright or license it globally. Either path would allow the company to add neurodegenerative screening to a platform already focused on chronic illness detection—expanding its clinical relevance while reinforcing its core strategy of early, accessible intervention. "This accessible, fast, and scalable solution is designed to support early intervention and targeted treatment strategies, with the ambition of reaching millions of patients globally in the coming years," said Vinicio Vargas, CEO at Ainnova and member of the Board of Directors of the joint venture company, Ai-nova Acquisition Corp. (AAC). "Adding the early detection of dementia that this patented technology presents us would go a long way to making us a leader in the industry of early disease detection." For context, Vision AI is a non-invasive diagnostic platform that integrates retinal imaging, blood pressure, and basic lab data to assess an individual's risk for a range of chronic illnesses. Using just two retinal images and vital sign inputs, the system applies four proprietary algorithms—trained on more than 2.3 million clinical cases—to evaluate risk for cardiovascular disease, type 2 diabetes, liver fibrosis, and chronic kidney disease. The technology is designed to be fast, low-cost, and scalable, with a mission of enabling earlier and broader access to preventative care. "Our purpose is to create the future of early disease detection in an accessible way, so that patients can get a preventive check-up anywhere, at a low cost, and easily," said Vargas in a previous statement. "We want to prevent patients with risk factors from developing other diseases that could have been avoided before they became a real problem. To this end, we are seeking to integrate new technologies into our portfolio within a single platform, both through our R&D efforts and through potential exclusive licenses or acquisitions." In parallel to the dementia expansion, Avant is in advanced discussions to acquire Ainnova Tech outright. The two companies currently operate under the Ai-nova Acquisition Corp. (AAC) structure, and a completed merger would unify operations, reduce internal complexity, and streamline the path to regulatory approval. The timing is strategic, with a key FDA pre-submission meeting scheduled for July. Management believes that consolidation will strengthen Avant's U.S. market entry while continuing to support real-world deployments abroad. "This milestone reflects our two-tiered strategy, rapid deployment in low-regulation markets where Vision AI operates as a screening tool, and simultaneous progress toward FDA clearance for the U.S. market," said Vargas. "Entering the U.S. will unlock significant commercial potential, and early engagement with regulators ensures we do so with speed, credibility, and a validated product." While many early-stage AI healthcare platforms remain in pilot or prototype phases, Avant's Vision AI is already live in multiple clinical settings across Latin America. The platform is currently being used in Chile, Mexico, and Brazil, where it's generating safety, performance, and usability data from real-world patient populations. That clinical feedback is being used to refine the algorithms and prepare the system for broader adoption. The company's broader vision is to integrate a growing number of diagnostic tools into a single unified platform—one that can deliver actionable, early-stage health insights from simple inputs like imaging, vital signs, and blood biomarkers. With global rights to the Vision AI platform held through AAC, and detection sensitivity exceeding 90% according to research cited by the NIH, Avant believes it is well-positioned to offer scalable early detection solutions across multiple healthcare systems. With dementia screening now on the roadmap, and additional diagnostic modules under evaluation, Avant's trajectory appears to be accelerating—from early validation toward international scale, and ultimately toward U.S. market penetration. Butterfly Network, Inc. (NYSE: BFLY) delivered strong Q1 results with $21.2 million in revenue, up 20% from the prior year, while expanding its AI footprint in medical imaging. Its Butterfly Garden program added two new AI development partners, and one app—HeartFocus—earned FDA clearance for real-world cardiac assessment. "Our results highlight the strength of our opportunities in medical education and enterprise adoption, while marking continued progress across our strategic initiatives, Octiv™ and Butterfly HomeCare," said Joseph DeVivo, President, CEO and Chairman of Butterfly Network. "With multiple avenues for growth and a team built to execute, we're well-positioned to deliver on the guidance we committed, while continuing to advance innovation and uphold our technology leadership." These developments align with the company's broader strategy to combine semiconductor-based ultrasound with machine learning and clinical workflow software. AptarGroup, Inc. (NYSE: ATR), through its subsidiary Aptar Digital Health, and AstraZeneca PLC (NASDAQ: AZN) have entered a licensing agreement to develop AI-powered screening algorithms for chronic kidney disease (CKD), aiming to support early detection through routine eye exams. "With early detection and timely treatment, patients are likely to experience better health outcomes," said Romain Marmot, President of Aptar Digital Health. "This collaboration aims to enhance the overall quality of care for patients with CKD by providing an innovative and effective early detection tool." The algorithms—originally developed by AstraZeneca using thousands of biomarkers and clinical data points—will enable ophthalmologists to screen for CKD during retinal fundus imaging, similar to existing diabetic screening methods. "Chronic kidney disease remains one of the most significant global health challenges, with persistently low diagnosis rates," said Mina Makar, Senior Vice President, Cardiovascular, Renal and Metabolism, AstraZeneca. "This partnership with Aptar represents an exciting opportunity to drive innovation in chronic kidney disease management and our commitment to enhance diagnostics in novel ways. We are collaborating at scale to deliver sustainable solutions for millions of people living with chronic kidney disease worldwide." Relay Therapeutics, Inc. (NASDAQ: RLAY) is leveraging its AI-augmented Dynamo® platform to accelerate drug discovery in precision oncology and genetic diseases. In Q1 2025, the company reduced R&D spend and focused its pipeline to support key clinical milestones, including its ReDiscover-2 Phase 3 breast cancer trial and a new vascular malformations study. "2025 is a year of execution across a range of high value clinical programs," said Sanjiv Patel, M.D., President and CEO of Relay Therapeutics. "The ongoing changes to our cost base are designed to enable a full funding of key initiatives including generating topline data from the ReDiscover-2 trial and clinical proof-of-concept data in vascular malformations." With $710 million in cash and a runway projected through 2029, Relay is positioned to reach topline data readouts without additional financing. The company also completed a global out-license of RLY-4008, reinforcing its commitment to capital efficiency and focused innovation. DISCLAIMER: Nothing in this publication should be considered as personalized financial advice. We are not licensed under securities laws to address your particular financial situation. No communication by our employees to you should be deemed as personalized financial advice. Please consult a licensed financial advisor before making any investment decision. This is a paid advertisement and is neither an offer nor recommendation to buy or sell any security. We hold no investment licenses and are thus neither licensed nor qualified to provide investment advice. The content in this report or email is not provided to any individual with a view toward their individual circumstances. Equity Insider is a wholly-owned subsidiary of Market IQ Media Group, Inc. ("MIQ"). MIQ has been paid a fee for Avant Technologies Inc. advertising and digital media from the company directly. There may be 3rd parties who may have shares Avant Technologies Inc., and may liquidate their shares which could have a negative effect on the price of the stock. This compensation constitutes a conflict of interest as to our ability to remain objective in our communication regarding the profiled company. Because of this conflict, individuals are strongly encouraged to not use this publication as the basis for any investment decision. The owner/operator of MIQ own shares of Avant Technologies Inc. which were purchased in the open market. MIQ reserves the right to buy and sell, and will buy and sell shares of Avant Technologies Inc. at any time thereafter without any further notice. We also expect further compensation as an ongoing digital media effort to increase visibility for the company, no further notice will be given, but let this disclaimer serve as notice that all material disseminated by MIQ has been approved by the above mentioned company; this is a paid advertisement, and we own shares of the mentioned company that we will sell, and we also reserve the right to buy shares of the company in the open market, or through other investment vehicles. While all information is believed to be reliable, it is not guaranteed by us to be accurate. Individuals should assume that all information contained in our newsletter is not trustworthy unless verified by their own independent research. Also, because events and circumstances frequently do not occur as expected, there will likely be differences between any predictions and actual results. Always consult a licensed investment professional before making any investment decision. Be extremely careful, investing in securities carries a high degree of risk; you may likely lose some or all of the investment.
Irish Times
21-05-2025
- Business
- Irish Times
Mortgage market shake-up brings new lenders offering greater flexibility
The mortgage market has had a shake-up and there might be something in it for you. Those borrowing for a home with a low building energy rating (Ber), public servants or anyone wanting discounted repayments in the first two years should know about new deals that are available from Avant and ICS . And if you haven't been living like a monk for six months and need mortgage approval in hours, not weeks, then Núa Money and MoCo 's artificial intelligence-driven process might be for you. Whether you're buying your first home or looking to switch mortgage, it's worth checking out the new kids on the block. Some of the best mortgage rates in recent years have been fixed rates, linked to high building energy-rated homes – until now that is. READ MORE Those with a low Ber are no longer stuck out in the cold. Avant's new Flex mortgage doesn't give a hoot about your insulation. It offers interest rates as low as 3.04 per cent for some borrowers – and you don't have to fix either, well, not for long. Flex is a bit like the old tracker mortgage in that it tracks a key euro zone lending rate – the 12-month Euro Interbank Offered Rate (Euribor) – the average interest rate at which European banks lend money to one another. So it's not the European Central Bank rate, but it behaves a bit like it. 'Every month, on the 10th of the month, Avant writes to brokers to confirm what the Euribor rate is on that date and that rate is held and available to the customer during that month,' mortgage broker Michael Dowling of Dowling Financial says. Avant adds a set margin to this rate, which will depend on your loan-to-value (LTV) ratio. For those with a 10 per cent deposit, or a loan-to-value higher than 80 per cent, a 1.1 percentage point margin is added. For those with a 20 per cent deposit or a loan-to-value below 80 per cent, the margin is 0.9 of a percentage point. The interest rate for Flex customers is set on the day you draw down your mortgage. It is fixed at that rate for the first 12 months of the mortgage, so Flex mortgage customers have certainty over their repayments the 12 months following at least. 'This is a tracker mortgage with a 12-month fixed element to it is how I would describe it,' Dowling says. So what are the rates like? At the time of writing, those borrowing 80 per cent of the value of the home can access a rate of 3.04 per cent. Those borrowing between 80 and 90 per cent of the value will be offered 3.14 per cent. A year into your mortgage, your rate is adjusted based on the 12-month Euribor market rate at that date. Though a fixed rate, the product retains some of the advantages of a variable rate. 'If after three months you felt nervous about what's happening with interest rates, you can switch out of it into a longer-term fixed rate with no penalty,' Dowling says. If after 12 months you want to change to a three or four-year fixed rate instead, you can do that too. 'The projections on this product are even better over the next number of months because the ECB is expected to reduce rates even further,' he says. Flex suits a number of people, says Margaret Barrett of broker Mortgage Navigators. If you're buying or switching mortgage on a home with a low Ber, the product will certainly pique interest as rates compare well with green rates from pillar banks. Someone who has a variable element to their income, like a bonus, will value the facility to overpay the mortgage without penalty, Barrett says. This is typically more limited for fixed rate mortgages. First-time buyers are typically borrowing 90 per cent loan-to-value, for which Bank of Ireland is offering a 3.1 per cent fixed rates long as you have an Ber A-rated property. While that interest rate is cheaper than Avant's, you have a greater capacity to overpay the mortgage with Flex and you don't have to spend on a retrofit to get the rate. The Flex will appeal to those with a low mortgage borrowings too, Barrett says. 'Some lenders have a minimum amount of borrowing, so their cheaper rates are only available if you are borrowing €250,000 or more, but Avant doesn't have that requirement. The Flex is available on mortgages over €100,000, and the Ber is irrelevant.' AIB's green rate for those whose mortgage is less than 50 per cent loan-to-value is 3 per cent, so the Flex is a competitive alternative, she says. Those self-building or availing of the Government First Home Scheme need not apply, however. Avant's Flex is not available to them. Indeed, Avant, Nua Money, MoCo and ICS don't lend for self-build or to those buying with the help of a scheme that puts a local authority charge on the property. Interest-only If you need money in the near term to renovate your home, to pay for childcare or to bridge an income gap while one earner takes time out, the new Flexi two-year interest-only option from ICS is worth considering, but with caveats. This rate gives owner occupiers a break in the first two years, where you pay only the interest on the loan, but you must take out a five-year fix. It is open to first-time buyers, movers and mortgage switchers and is available to those borrowing up to 90 per cent of the value of their home, with a minimum loan size of €100,000. Interest-only for the first two years means reduced payments. Capital and interest repayments apply for the remaining term. Rates are from 4.25 per cent up to 4.4 per cent, fixed for five years – so they are not the cheapest. If you borrow €250,000 over 30 years at a rate of 4.25 for example, you'd pay €1,229 a month on a normal capital and interest mortgage. With ICS's two-year interest-only feature, your mortgage repayment for the first two years will only be €885 a month. But your mortgage will move to a capital and interest mortgage at the start of year three with repayments increasing to €1,273 a month; that's an overnight jump of €388 a month. Just like Avant's back-to-the-future, non-tracker tracker product, this has a hint of the Celtic Tiger to it. Some borrowers ran into difficulty back then with features like this. 'Personally if a first-time buyer is looking for interest only for the first two years, I'd be concerned for when the repayments ratcheted up,' Dowling says. Public-sector workers The ICS Flexi product is not the most competitive rate in the market right now, but there is a sweetener for public-sector workers, Barrett says. Whether you are a public-sector worker or you are buying a house with one, the Flexi will enable you to borrow several points further up the salary scale than with some other banks. 'For customers looking for maximum borrowings, the interest rate might not be the main decider,' Barrett says. For joint mortgage applications where the public servant is not the main earner, ICS will assess their income five points up their pay scale. Take the example of the primary earner who works in the private sector worker and their teacher partner who are applying for a mortgage. The primary earner is earning €65,000 and the secondary earner teacher is on point three of the salary scale, earning €43,469. There is even more flexibility for two public-sector applicants For the purposes of assessing how much they can borrow, the teacher's income will be assessed five points up at point eight on the salary scale, bumping up their assessable income to €52,021. This enables the couple to borrow more at €468,084 – almost €35,000 more than if they were assessed on the current teaching salary. Their mortgage repayments, interest-only for the first two years, will be €1,716 a month. After two years, this will move to capital and interest payments of €2,425 a month for the remaining three years of the five-year fixed period. Under standard criteria, where the public-sector applicant would be assessed at three points up, the loan size would be €451,008, with capital and interest repayments of €2,258 a month. There is even more flexibility for two public-sector applicants. The main earner will be assessed at three points up the salary scale, and the secondary earner at five points up. MoCo and Nua will lend two points up the salary scale while Avant will lend one point higher. PTSB and Bank of Ireland don't offer the feature. AIB will also go three points higher, but it's not as generous as ICS's new feature, Dowling says. While the Flexi enables public servants to borrow more, their mortgage will be more expensive in the longer run due to the interest-only start. Repayment ability If you need mortgage approval in hours, not weeks, then new Irish lender Núa Money might be the one for you. 'They are the first real digital mortgage; their speed of accepting a client is unparalleled,' Barrett says. 'You could submit something at 9.30am and have a full loan offer by 10.30am.' How do they do it? They sidestep the cottage industry that proving repayment ability has become since the financial crash. This is where the mortgage applicant must live like a saint for six months, providing reams of bank statements as evidence. The broker would then comb through the applicant's financial history looking for misdemeanours and proof of ability to repay. Guess what? Núa Money doesn't care about your bank statements. 'Not needing to demonstrate repayment capacity is a game changer for the Irish market,' Barrett says. 'Núa has decided if you have the net disposable income on the assessment calculator, you have demonstrated you can pay.' People whose dream home came up for sale, but whose bank statements for the previous six months weren't pristine, value Núa's pragmatism and speed, she says. Brokers are happy to be absolved of this grunt work too, she says. This is challenging the legal system which is obsessed with getting hard copies of everything and producing original signatures Núa says it is catering to the 'thousands of customers with the financial capacity to afford a mortgage who are being locked out by outdated lending models'. The lender also offers loans to immigrant visa holders who have been here for six months and have passed work probation. Bonus income is looked on more favourably too. Rates start at a 3.6 per cent for a three-year fix for customers with a loan-to-value ratio of 60 per cent. Those customers will get 3.65 per cent if they fix for five years. For those with loan-to-value of 70 per cent, the three and five-year rates are 3.9 and 3.95 per cent respectively. These mortgage rates aren't the cheapest on the market, but the product will appeal to buyers wanting to move fast and avoid the faff. 'I can get a mortgage approval letter in one hour and a loan document in two hours,' Dowling says. 'With AIB, Bank of Ireland, PTSB and Avant, it takes 10 to 15 working days.' Electronic rather than physical signatures speed up the legalities too. 'This is challenging the legal system which is obsessed with getting hard copies of everything and producing original signatures. They are light years ahead of the other banks,' Dowling says. Austrian-owned MoCo is also using technology to speed things up. All applications are done online using Open Banking – a system that enables banks to share data. No need to order bank statements. For those borrowing 90 per cent loan-to-value, MoCo offers a three or five-year fix of 3.95 per cent. For those borrowing 60 per cent, the rate for a three or five-year fix is 3.6 per cent.
Irish Independent
21-05-2025
- Business
- Irish Independent
Thousands to get refunds after being overcharged interest on credit cards
Avant Money said it had identified what it called an 'administrative error' that led to 4,200 of its card customers paying too much interest. In what is just the latest instance of overcharging by financial institutions in this country, Avant Money has written to customers affected. One customer, a risk manager from Co Meath who does not want to be identified, said he got an email out of the blue telling him he was due a refund of €544.48. This was to cover 'any excess interest charged, including compensatory interest is due to you', the email said. 'I thought it was a scam at first as I haven't had an Avant Money card for four years.' This meant that these customers had an incorrect interest rate applied to cash transactions He contacted a colleague he knows uses an Avant credit card and his colleague told him he also got an email from the card provider, and had been advised to expect a refund and compensation totalling €340. Contacted by the Irish Independent, Avant Money said: 'In March, we self-identified an administrative error affecting the interest rate on a number of customer credit card accounts following an internal review. 'This meant that these customers had an incorrect interest rate applied to cash transactions for a period of time.' It said around 4,200 customers had been affected by the interest rate issue, with an average refund amount of €20.43. Asked whether the Central Bank had been informed about the overcharging, Avant confirmed it did tell the regulator. 'While the error was resolved within the required regulatory timeframe, meaning there was no obligation to notify the Central Bank, we have chosen to do so as a courtesy,' the bank said. The Central Bank said it could not comment on its supervisory engagement, but continued to engage with the firm. It said it expected all regulated firms to have adequate systems and controls in place and where issues that affected customers arose, they should be addressed and rectified, with the overarching objective of protecting customers' interests. Last month, Avant Money revealed it is now a fully licensed bank in this market. It is keeping its Avant Money name for now, but is expected in time to change to the Bankinter brand, the name of its Spanish parent company. Just before Christmas, the Central Bank issued data showing up to 400,000 consumers in Ireland are needlessly paying some of the highest interest rates on their credit cards. It said these people were paying rates of more than 23pc, when they could sign up for cards with much lower charges. Since 2022, legislative changes have meant new credit card accounts cannot have an annual percentage rate (APR) of more than 23pc. But a review by the Central Bank of Ireland has found that, of the approximately 1.3 million credit card accounts in Ireland, more than 400,000 are on higher APRs that pre-date this legislation. Meanwhile, there have been a string of overcharging issues by banks and non-bank lenders recently. Last November, it was disclosed that tens of thousands of homeowners with mortgages originally from Ulster Bank would be compensated after a blunder meant they were overcharged interest. The mortgages have been sold to AIB, PTSB and vulture funds. Some of the affected customers have since redeemed their mortgages. About 90,000 former Ulster Bank mortgage accounts were wrongly charged. Last May, AIB had to apologise for a second blunder in its handling of mortgages it bought from Ulster Bank. In February last year, Pepper Advantage admitted an error in its repayment process, which has led to repayments for about 2,500 borrowers being lower than they should be.
Yahoo
20-05-2025
- Business
- Yahoo
How much can I borrow with a personal loan if I have bad credit?
Lenders that offer loans for bad credit may accept FICO scores as low as 550 or may not require a credit score at all. Every lender has different eligibility requirements and maximum loan amounts. Upstart, Avant and LendingPoint are three of the best lenders for poor credit due to their lending models, APR ranges and repayment terms. Many lenders offer personal loans between $1,000 and $50,000. If your credit is poor, the amount you qualify for will depend on multiple factors. You may also face higher rates with a bad credit loan, which can make your monthly payment pricey. This makes it important to shop around and find the best bad credit loan rates available. That said, there are lenders that will work with you regardless of your credit history — but it might limit the amount you are eligible to borrow. The lower your credit score, the less likely you are to qualify for a lender's highest advertised loan amount. However, lenders may still consider you based on your credit history, your current debts and your income to determine how much you can borrow. Your credit score is among the most important factors to lenders when you apply for a loan. Most consider a bad credit score as a FICO score below 580 or a Vantage score below 601. When you apply, lenders will conduct a hard credit check to look at your credit report. Your credit report houses all of your repayment information and credit history, including any missed payments, open accounts and your debt-to-income ratio. Lenders also evaluate your credit score to gauge your creditworthiness — the higher your score, the more likely you are to be offered a larger loan. If you apply with a bad credit lender, you could be approved with a score as low as 550. Still, a higher credit score could mean access to more funds. Your debt-to-income (DTI) ratio is the percentage of how much you owe versus your income. To calculate your DTI, add your monthly debt payments — such as student loans, auto loans, mortgage payments and credit card balances — and divide them by your gross monthly income. You can also use a debt-to-income ratio calculator if you don't want to do the math by hand. Ideally, most lenders prefer DTIs under 36 percent, but some will accept ratios as high as 50 percent. The lower your DTI, the more confidence a lender will have in your ability to take on more debt. If your DTI is well over 50 percent, consider dedicating time to paying down your existing debt before taking out another loan. If you need the cash immediately, look for lenders that don't have a DTI specification or accept high ratios. Lenders that accept borrowers with bad credit typically use nontraditional aspects of your finances to determine how much you can borrow. This may take the form of a monthly or annual income requirement. Upstart, for example, offers unsecured loans up to $50,000 and doesn't have a credit score requirement. But it does have a minimum income requirement of $12,000. In addition, Upstart — and some other lenders — considers your education history alongside your credit profile. Adding a cosigner with a good or excellent credit may persuade a lender to approve you for a higher loan amount. A cosigner shares legal responsibility for repaying the loan with you. When you have a cosigner, the lender knows that if you miss a payment, it still has an alternate way to get the money that is due. Not all lenders allow you to add a cosigner to their loan application. Instead, they may only allow you to apply with a co-borrower. A co-borrower, unlike a cosigner, has a right to access the personal loan funds. They also share a responsibility for repaying the loan. If you want to use a cosigner or co-borrower, check on the lender's website or with its customer service before applying. There are personal loan alternatives available if you don't qualify for other options. Although these can be the easiest loans to get if you have poor credit, they have risks. You should be wary of the high interest rates and fees often associated with payday loans and no-credit-check loans. Emergency loans: Many emergency loans often have a high interest rate and fees if your credit score is poor. Payday loans: Because of minimal regulation, payday loans often have triple-digit interest rates and fees. You should consider them as a last resort. No-credit-check loans: A no-credit-check loan is another last-resort option. This type of loan is made for people with poor credit, and the APRs and fees can be extremely high. Should you take out a personal loan if you have bad credit? Some types of bad credit loans are more risky than others, and a bad credit personal loan may be the least risky of your options. They have long repayment periods, and the APR maxes out at 35.99 percent. By comparison, you only have two weeks to repay a payday loan and APRs may exceed 650 percent. Even when you have a poor credit score, there are many places to get a bad credit personal loan. The potential for high fees and a high annual percentage rate (APR) makes it important to compare bad credit lenders and find the best loan terms possible. You can find bad credit personal loans online. Lenders like Upstart, Avant and LendingPoint offer prequalification, which allows you to preview your possible rates without hurting your credit score. But while their minimum rates are low, you will likely receive a higher APR if you don't try to improve your credit score before applying. Lender APR range Loan amount Loan term Minimum credit score Upstart 6.60%-35.99% $1,000–$50,000 3 - 5 years No Requirement Avant 9.95%-35.99% $2,000–$35,000 2 - 5 years 550 LendingPoint 7.99%-35.99% $1,000–$36,500 2 - 6 years 600 Loans for bad credit may allow you to borrow anywhere from $1,000 to $50,000. Getting approved for a personal loan with bad credit may be difficult, but it's not impossible. Look for lenders that specialize in poor credit borrowers or use a qualifying co-signer to increase your chances of being approved. While it may seem tempting to apply when you find a lender you qualify for, read the terms and conditions first to check for hidden fees or requirements not advertised online. Also, if the lender offers prequalification, try it before starting an application. Error in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data
Yahoo
20-05-2025
- Business
- Yahoo
Avant Technologies and Ainnova in Talks to Obtain Innovative Technology in Preventative Health Reporting
LAS VEGAS, May 20, 2025 /CNW/ -- Avant Technologies, Inc. (OTCQB: AVAI) ("Avant" or the "Company"), and its JV partner, Ainnova Tech, Inc., (Ainnova), a leading healthcare technology company focused on revolutionizing early disease detection using artificial intelligence (AI), today announced the companies are in talks with an international healthcare innovation company to license or potentially acquire its patented early disease detection technology. If successful, it's a global license or acquisition that has the potential to revolutionize preventive health reporting and to generate correlations for future detection of new diseases without the need for all the patient's data. Avant and Ainnova continue to grow the footprint and capabilities of their technology portfolio with the goal of being a leader in early disease detection using the Company's signature AIdriven Vision AI technology platform. Vinicio Vargas, Chief Executive Officer at Ainnova and member of the Board of Directors of the joint venture company, Ai-nova Acquisition Corp., said of the Company's aim to continue to add to its portfolio, "Our purpose is to create the future of early disease detection in an accessible way, so that patients can get a preventive check-up anywhere, at a low cost, and easily. We want to prevent patients with risk factors from developing other diseases that could have been avoided before they became a real problem. "To this end, we are seeking to integrate new technologies into our portfolio within a single platform, both through our R&D efforts and through potential exclusive licenses or acquisitions." Avant and Ainnova see the retina as a new vital sign, but also understand that leveraging the results of laboratory tests and basic patient data can all work in concert to provide a comprehensive health report. Vargas added, "We have already integrated an exclusive license for four algorithms into our Vision AI platform, and we are now in talks to license and potentially acquire an innovative technology that would be a game changer in our industry." Avant will inform its shareholders of any updates at an appropriate time. About Ainnova Tech, is a Nevada-based healthtech startup with headquarters in San Jose, Costa Rica, and Houston, Texas. Founded by an experienced and innovative team that is dedicated to leveraging artificial intelligence for early disease detection. Recognized with multiple global awards and renowned partnerships with hospitals and medical device companies, we proudly introduce Vision AI – our cutting-edge platform designed to prevent blindness and detect the early onset of diabetes. Explore how Ainnova is revolutionizing healthcare through advanced technology and proactive solutions. About Avant Technologies, Inc. Avant Technologies, Inc. is an emerging technology company developing solutions in artificial intelligence in healthcare. With a focus on pushing the boundaries of what is possible in AI and machine learning, Avant serves a diverse range of industries, driving progress and efficiency through state-of-the-art technology. More information about Avant can be found at You can also follow us on social media at: Forward-Looking StatementsCertain statements contained in this press release may constitute "forward-looking statements." Forward-looking statements provide current expectations of future events based on certain assumptions and include any statement that does not directly relate to any historical or current fact. Actual results may differ materially from those indicated by such forward-looking statements because of various important factors as disclosed in our filings with the Securities and Exchange Commission located at their website ( In addition to these factors, actual future performance, outcomes, and results may differ materially because of more general factors including (without limitation) general industry and market conditions and growth rates, economic conditions, governmental and public policy changes, the Company's ability to raise capital on acceptable terms, if at all, the Company's successful development of its products and the integration into its existing products and the commercial acceptance of the Company's products. The forward-looking statements included in this press release represent the Company's views as of the date of this press release and these views could change. However, while the Company may elect to update these forward-looking statements at some point in the future, the Company specifically disclaims any obligation to do so. These forward-looking statements should not be relied upon as representing the Company's views as of any date after the date of the press release. Contact:Avant Technologies, View original content to download multimedia: SOURCE Avant Technologies Inc. View original content to download multimedia:
